Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported improved financial metrics, including a reduction in net loss and operating losses, along with a strong cash position. The Q&A highlighted steady growth prospects for recombinant bovine transferrin and potential vaccine development using C1 technology, both of which are positive indicators. The company has successful partnerships, like with Intralink and Phibro, and a promising market strategy focusing on cultured meat. Despite some unclear management responses, the overall sentiment leans positive, with no major negative indicators to suggest a downturn.
Key Financial Performance
Total Revenue $1.1 million, representing an increase of 182% year-over-year compared to $394,000 in Q1 2025. The increase was driven by higher research and development revenue of $220,000, ongoing grant revenues of $277,000 funded by CEPI and the Gates Foundation, and milestone revenue of $200,000 recognized under the Inzymes Agreement.
Total Cost of Revenue $792,000, compared to $298,000 in Q1 2025. The increase was primarily related to higher activity levels associated with research and development and grant-funded programs, particularly under the CEPI and Gates Foundation initiatives.
Internal Research and Development Expenses Decreased by approximately 4% year-over-year to $476,000, primarily reflecting a slight reduction in the number of active internal research and commercial initiatives during the quarter.
G&A Expenses Increased by $159,000 or 10% year-over-year to $1.8 million. The increase was primarily driven by higher legal and accounting expenses of $221,000 and rebranding and business development activities, partially offset by lower share-based compensation expenses of $110,000 and reduced insurance costs.
Loss from Operations Improved by approximately 5% year-over-year to $1.9 million compared to $2 million in Q1 2025. The improvement was mainly driven by the significant increase in revenue and lower research and development expenses, partially offset by higher costs associated with revenue-generating activities and increased G&A expenses.
Net Loss $1.95 million or $0.05 per share, compared to $2.03 million or $0.07 per share in Q1 2025. The improvement was due to increased revenue and lower research and development expenses.
Cash Position $6.6 million in cash, cash equivalents, restricted cash, and investment-grade securities as of the end of Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Proliant Health & Biologics' Albufree Dx: Commercial launch of Albufree Dx recombinant human albumin produced using Dyadic's platform technology. Dyadic is eligible to receive a share of the profits from product sales.
Inzymes' recombinant non-animal bovine chymosin: Successfully commercialized recombinant non-animal bovine chymosin, validating Dyadic's technology and commercialization models.
Recombinant bovine transferrin: Expanded customer engagement and received initial purchase orders within the cultivated meat segment.
Recombinant growth factors and cell culture components: Continued development to support transition towards animal-free media systems.
Recombinant animal origin-free DNase-1: Commercially launched with Fermbox Bio and distributed through IBT Bioservices' global channels.
Food and Nutrition: Focused on large global markets for animal-free proteins. Agreement with BRIG BIO for recombinant bovine alpha-lactalbumin development and ongoing development of recombinant human lactoferrin.
Bioindustrial markets: Partnership with Fermbox Bio advancing manufacturing scale-up and commercialization activities, including EN3ZYME product expansion into Asia Pacific.
Revenue growth: Total revenue for Q1 2026 was $1.1 million, a 182% increase from Q1 2025, driven by research and development revenue, grant revenues, and milestone revenue.
Cost management: Maintained disciplined cash management with operating expenses generally in line with 2025 levels.
Cash position: Ended Q1 2026 with $6.6 million in cash and equivalents, providing runway into Q2 2027.
Strategic partnerships: Collaborations with Gates Foundation and CEPI for biopharmaceutical programs, generating non-dilutive funding and validating the C1 platform.
Diversified revenue streams: Building multiple paths to revenue through direct sales, licensing, milestone payments, and strategic collaborations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption Challenges: The company is still in the early stages of transitioning to a commercially focused biotechnology company, which may pose challenges in achieving market adoption and scaling revenues.
Revenue Dependency: The company is building multiple revenue streams but remains dependent on successful commercialization and partnerships, which may not materialize as expected.
Regulatory and Development Risks: Development and commercialization of recombinant proteins and enzymes involve regulatory hurdles and technical challenges that could delay or hinder progress.
Financial Sustainability: Despite revenue growth, the company reported a net loss of $1.95 million for Q1 2026, raising concerns about financial sustainability and the need for disciplined cash management.
Operational Risks: Higher costs associated with revenue-generating activities and increased G&A expenses could impact profitability and operational efficiency.
Supply Chain and Manufacturing Risks: Reliance on external manufacturing partners like Fermbox Bio introduces risks related to supply chain reliability and manufacturing scalability.
Competitive Pressures: The company operates in highly competitive markets, including life sciences, food and nutrition, and industrial applications, which could impact market share and pricing.
Strategic Execution Risks: The company’s strategy to expand through partnerships and distribution agreements requires effective execution to achieve desired outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects growth in product revenues across its Life Sciences and Food and Nutrition business segments, supported by recent product launches, expanding commercial activities, and growing customer engagement.
Cash Runway: Dyadic anticipates its existing cash resources will provide a cash runway into Q2 2027.
Operating Expenses: The company plans to maintain operating expenses generally in line with 2025 levels.
Strategic Partnerships and Capital Markets: Dyadic will continue to evaluate strategic partnerships and capital markets opportunities to strengthen its balance sheet and support long-term growth.
Customer Sampling and Product Development: Customer sampling for recombinant bovine alpha-lactalbumin is expected to begin in mid-2026, with ongoing development activities for recombinant human lactoferrin and other functional proteins.
Market Adoption: The company is seeing early indicators of market adoption for recombinant bovine transferrin in the cultivated meat segment, with expectations for scaling alongside customer production.
Commercialization Strategy: Dyadic plans to emphasize larger strategic partnerships, leverage established commercial channels, expand direct product opportunities selectively, and maintain disciplined expense management.
Biopharmaceutical Programs: The company continues advancing biopharmaceutical collaborations, including those funded by the Gates Foundation and CEPI, to support recombinant vaccine development and monoclonal antibody production.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the ramp of recombinant bovine transferrin over the next few years?
A:The ramp is expected to be steady but not hockey stick level growth. Initial pilot scales are growing with small kilogram orders. Significant volume increases will occur with regulatory approval of cultivated meat. Bovine transferrin is also used in serum-free cell culture applications, diagnostics, and other workflows, which will contribute to revenue growth.
Q:Can C1 technology help with potential vaccines for Hantavirus?
A:Yes, C1 technology can help. It has advanced since COVID, offering faster, cheaper, and higher-quality production of complex proteins. The CEPI program has demonstrated rapid development of stable cell lines and high-quality proteins. The technology is well-positioned for monoclonal antibodies and vaccines in pandemic situations.
Q:How is the relationship with Intralink progressing?
A:The relationship with Intralink has expanded to include Europe. Significant initial success has been achieved in Japan with customer engagement and sample shipments. Intralink helps target distributors and customers efficiently, supporting business development activities.
Q:What are the next steps after the IBT arrangement support channel receives inventory?
A:The first products (DNase-1 and transferrin) have shipped and will be distributed through IBT's global network. Sales teams will target academic institutions, hospitals, and research organizations. Additional products like recombinant alpha-lactalbumin and human transferrin will follow.
Q:What is the cash burn estimate for midyear?
A:The cash burn is expected to remain at the same level as previous years, less than $5.7 million. With $6.6 million in cash and equivalents as of March, the company has enough runway into next year.
Q:Are there any ongoing relationships with Codexis or royalties from Fermbox?
A:There are no publicly reportable relationships with Codexis. Royalties from Fermbox are expected in 2026 as the focus is on growing products.
Q:What is the status of the partnership with Phibro?
A:Phibro is expected to enter clinical trials this year, with potential approval in the next 12-24 months. Milestones are associated with regulatory approval, and news flow is anticipated in 2026-2027. The partnership has been successful in terms of technology performance.
Q:Will the company need to add headcount as it ramps up in 2027?
A:Additional support may be needed for product shipments and manufacturing as sales scale, but hiring will be revenue-dependent. The company is currently leveraging partnerships like IDT for sales efforts.
Q:What is the potential for cultured meat demand versus non-animal dairy?
A:Cultured meat has more acute demand due to the need to reduce production costs and regulatory approvals. Non-animal dairy demand is growing but requires large-scale production to compete with milk-derived products. Cultured meat is expected to drive nearer-term revenues, while non-animal dairy has long-term potential.
Q:Which geographies have the least regulatory hurdles for cultured meat?
A:The U.S. is considered to have the least regulatory hurdles due to the GRAS-certified organism pathway. The EU may have more regulatory challenges, but the demand for protein and cleaner nutrition supports market growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or detailed projections for certain milestones, such as the exact timing of royalties from Fermbox and the scale-up of non-animal dairy production. Additionally, responses about regulatory hurdles and market adoption were somewhat general, lacking precise data or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEPI collaboration
DNase
IBT
OEM distribution
activity
agreement
animal protein
antibody vaccine
application
capability
cell culture
channel product
customer
development
economics
example
investor
launch
licensing opportunity
manufacturing
market product
milestone
monoclonal antibody
nutrition
order
partner
partnership
platform
production
progress
protein enzyme
relationship
revenue
scale
technology
transition
DYAI Transcript
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Positive5-14
The company reported improved financial metrics, including a reduction in net loss and operating losses, along with a strong cash position. The Q&A highlighted steady growth prospects for recombinant bovine transferrin and potential vaccine development using C1 technology, both of which are positive indicators. The company has successful partnerships, like with Intralink and Phibro, and a promising market strategy focusing on cultured meat. Despite some unclear management responses, the overall sentiment leans positive, with no major negative indicators to suggest a downturn.
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Positive3-26
The earnings call summary shows strong financial performance with a 25% revenue increase and a 33% net income rise. Despite increased operating expenses, cash flow improved by 15%. The strategic initiatives and biopharmaceutical program updates were not detailed, but the financial results suggest positive market sentiment. The lack of specific shareholder return plans and operational updates slightly tempers the outlook, but the overall positive financial indicators and market expansion support a positive sentiment.
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Neutral12-9
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals mixed signals. While there are positive developments like new partnerships and strategic market expansion, financial metrics show increased losses and expenses. The Q&A highlights potential growth in DNase1 markets and new partnerships, but lacks specific financial guidance. Increased cash reserves provide some stability, yet the lack of detailed financial projections and increased operating losses offset the positives, leading to a neutral sentiment.
DYAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
